Zagouri, Flora http://orcid.org/0000-0001-7153-6556
Koliou, Georgia-Angeliki
Dimitrakopoulos, Foteinos
Papadimitriou, Christos
Binas, Ioannis
Koutras, Angelos
Papakostas, Pavlos
Markopoulos, Christos
Venizelos, Vasileios
Xepapadakis, Grigorios
Andrikopoulou, Αngeliki
Karanikiotis, Charisios
Psyrri, Amanda
Bafaloukos, Dimitrios
Kosmidis, Paris
Aravantinos, Gerasimos
Res, Eleni
Mauri, Davide
Koumarianou, Anna
Petraki, Kalliopi
Tsipoura, Anna
Pectasides, Dimitrios
Gogas, Helen
Fountzilas, George
Funding for this research was provided by:
Hellenic Cooperative Oncology Group
Article History
Received: 23 July 2021
Revised: 13 December 2021
Accepted: 6 May 2022
First Online: 24 May 2022
Competing interests
: FZ: Honoraria and advisory role: AstraZeneca, Daiichi, Eli-Lilly, Merck, Novartis, Pfizer and Roche. CP: Honoraria and advisory role: Novartis, AstraZeneca, Genesis, MSD, Amgen, Pfizer, Merck and Roche. Research grants: BMS and Roche. AK: consulting or advisory role: Novartis, Roche, Genesis, AstraZeneca. Speaker’s bureau: GSK. Travel: Sanofi-Aventis, Astellas, Genesis, Amgen, BMS, Merck Serono. PP: advisory role: Roche, Merck, Genesis Pharmaceuticals, Honoraria: Roche, Merck. AP: consulting or advisory role: Amgen, Merck Serono, Roche, BMS, AstraZeneca, MSD, Honoraria: Amgen, Merck Serono, Roche, BMS, AstraZeneca, MSD. Research funds: BMS Kura. PK: Honoraria: Novartis, MSD, Pfizer. Travel: Pfizer, MSD, Genesis. GA: advisory boards: Novartis, BMS, Roche Hellas, Astra Zeneca, Sanofi, Amgen, Genesis Pharma, Merck, Pfizer. ER: consulting or advisory role: Novartis; Honoraria: Novartis; Travel: Genesis Pharmaceuticals, Pfizer, Roche, Bristol-Myers Squibb, Genekor. AK: Advisory Role: Genesis Pharma. Honoraria: Pfizer. Speaker’s bureau: Roche. Research funding: Merck. Travel: MSD. Educational grants: Novartis, Pfizer, Merck, Roche, BMS, MSD, Genesis, and Ipsen. DP: advisory role: Roche, MSD, Astellas. Honoraria: Roche, MSD, Astellas. HG: Advisory Role: Bristol-Myers Squibb, MSD Oncology, Amgen, Novartis, Roche, Pierre-Fabre, Honoraria: Bristol-Myers Squibb, MSD Oncology, Roche, Amgen, Novartis, research funding (institution): Bristol-Myers Squibb, Roche, MSD Oncology, Travel: Roche, Bristol-Myers Squibb. George Fountzilas: Advisory Board of Pfizer, Sanofi and Roche. Honoraria from AstraZeneca. Stock ownership: Genprex, Daiichi Sankyo, RFL Holdings, Formycon. The remaining authors declare no competing interests.
: All patients provided written informed consent before participating in the study. The clinical protocol was approved by the Institutional Review Boards in participating centres, by the National Organization for Medicines and by the National Ethics Committee and was registered in the Australian New Zealand Clinical Trials Registry (ACTRN12610000151033). The study was conducted in accordance with the ethical principles that have their origins in the Declaration of Helsinki.
: Not applicable.